Go Pro
→ Trump's New Dollar (From Porter & Company) (Ad)tc pixel Free NRIX Stock Alerts

Nurix Therapeutics (NRIX) Competitors

Nurix Therapeutics logo
$22.99 -0.35 (-1.50%)
Closing price 04:00 PM Eastern
Extended Trading
$23.00 +0.02 (+0.07%)
As of 04:42 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.
Compare

NRIX vs. KYMR, ARWR, PTGX, IBRX, and TGTX

Should you buy Nurix Therapeutics stock or one of its competitors? Nurix Therapeutics's main competitors and comparable companies include Kymera Therapeutics (KYMR), Arrowhead Pharmaceuticals (ARWR), Protagonist Therapeutics (PTGX), ImmunityBio (IBRX), and TG Therapeutics (TGTX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nurix Therapeutics compare to Kymera Therapeutics?

Nurix Therapeutics (NASDAQ:NRIX) and Kymera Therapeutics (NASDAQ:KYMR) are both mid-cap healthcare companies, but which is the better business? We will compare the two businesses based on the strength of their valuation, risk, earnings, profitability, media sentiment, institutional ownership, dividends and analyst recommendations.

Nurix Therapeutics currently has a consensus price target of $34.21, suggesting a potential upside of 46.96%. Kymera Therapeutics has a consensus price target of $133.21, suggesting a potential upside of 21.89%. Given Nurix Therapeutics' higher probable upside, equities analysts clearly believe Nurix Therapeutics is more favorable than Kymera Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
Kymera Therapeutics
1 Sell rating(s)
2 Hold rating(s)
22 Buy rating(s)
1 Strong Buy rating(s)
2.88

Nurix Therapeutics has higher revenue and earnings than Kymera Therapeutics. Kymera Therapeutics is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M28.77-$264.46M-$3.45N/A
Kymera Therapeutics$39.21M231.76-$311.35M-$3.24N/A

Nurix Therapeutics has a beta of 1.82, suggesting that its stock price is 82% more volatile than the broader market. Comparatively, Kymera Therapeutics has a beta of 1.98, suggesting that its stock price is 98% more volatile than the broader market.

Kymera Therapeutics has a net margin of -285.33% compared to Nurix Therapeutics' net margin of -928.44%. Kymera Therapeutics' return on equity of -21.22% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics-928.44% -76.09% -57.31%
Kymera Therapeutics -285.33%-21.22%-19.21%

In the previous week, Nurix Therapeutics had 4 more articles in the media than Kymera Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 4 mentions for Kymera Therapeutics. Kymera Therapeutics' average media sentiment score of 0.34 beat Nurix Therapeutics' score of 0.29 indicating that Kymera Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Kymera Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Kymera Therapeutics beats Nurix Therapeutics on 10 of the 15 factors compared between the two stocks.

How does Nurix Therapeutics compare to Arrowhead Pharmaceuticals?

Nurix Therapeutics (NASDAQ:NRIX) and Arrowhead Pharmaceuticals (NASDAQ:ARWR) are both mid-cap healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their media sentiment, dividends, institutional ownership, profitability, risk, earnings, analyst recommendations and valuation.

In the previous week, Nurix Therapeutics had 2 more articles in the media than Arrowhead Pharmaceuticals. MarketBeat recorded 8 mentions for Nurix Therapeutics and 6 mentions for Arrowhead Pharmaceuticals. Nurix Therapeutics' average media sentiment score of 0.29 beat Arrowhead Pharmaceuticals' score of 0.17 indicating that Nurix Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Arrowhead Pharmaceuticals
1 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nurix Therapeutics currently has a consensus target price of $34.21, indicating a potential upside of 46.96%. Arrowhead Pharmaceuticals has a consensus target price of $98.31, indicating a potential upside of 51.77%. Given Arrowhead Pharmaceuticals' higher probable upside, analysts plainly believe Arrowhead Pharmaceuticals is more favorable than Nurix Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80
Arrowhead Pharmaceuticals
1 Sell rating(s)
3 Hold rating(s)
10 Buy rating(s)
0 Strong Buy rating(s)
2.64

Arrowhead Pharmaceuticals has higher revenue and earnings than Nurix Therapeutics. Arrowhead Pharmaceuticals is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nurix Therapeutics$83.98M28.77-$264.46M-$3.45N/A
Arrowhead Pharmaceuticals$829.45M11.00-$1.63M-$2.25N/A

Nurix Therapeutics has a beta of 1.82, suggesting that its share price is 82% more volatile than the broader market. Comparatively, Arrowhead Pharmaceuticals has a beta of 1.3, suggesting that its share price is 30% more volatile than the broader market.

62.6% of Arrowhead Pharmaceuticals shares are owned by institutional investors. 6.7% of Nurix Therapeutics shares are owned by company insiders. Comparatively, 3.6% of Arrowhead Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Arrowhead Pharmaceuticals has a net margin of -47.79% compared to Nurix Therapeutics' net margin of -928.44%. Arrowhead Pharmaceuticals' return on equity of -60.06% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Nurix Therapeutics-928.44% -76.09% -57.31%
Arrowhead Pharmaceuticals -47.79%-60.06%-17.37%

Summary

Nurix Therapeutics and Arrowhead Pharmaceuticals tied by winning 8 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to Protagonist Therapeutics?

Protagonist Therapeutics (NASDAQ:PTGX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their analyst recommendations, institutional ownership, media sentiment, dividends, risk, profitability, valuation and earnings.

Protagonist Therapeutics presently has a consensus price target of $147.13, indicating a potential upside of 5.04%. Nurix Therapeutics has a consensus price target of $34.21, indicating a potential upside of 46.96%. Given Nurix Therapeutics' higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than Protagonist Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Protagonist Therapeutics
0 Sell rating(s)
2 Hold rating(s)
16 Buy rating(s)
0 Strong Buy rating(s)
2.89
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Nurix Therapeutics had 6 more articles in the media than Protagonist Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 2 mentions for Protagonist Therapeutics. Protagonist Therapeutics' average media sentiment score of 0.83 beat Nurix Therapeutics' score of 0.29 indicating that Protagonist Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Protagonist Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Protagonist Therapeutics has higher earnings, but lower revenue than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than Protagonist Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Protagonist Therapeutics$46.02M196.97-$130.15M$1.03136.00
Nurix Therapeutics$83.98M28.77-$264.46M-$3.45N/A

Protagonist Therapeutics has a net margin of 29.40% compared to Nurix Therapeutics' net margin of -928.44%. Protagonist Therapeutics' return on equity of 12.03% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Protagonist Therapeutics29.40% 12.03% 11.23%
Nurix Therapeutics -928.44%-76.09%-57.31%

Protagonist Therapeutics has a beta of 1.53, indicating that its stock price is 53% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.82, indicating that its stock price is 82% more volatile than the broader market.

98.6% of Protagonist Therapeutics shares are owned by institutional investors. 5.2% of Protagonist Therapeutics shares are owned by insiders. Comparatively, 6.7% of Nurix Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Summary

Protagonist Therapeutics beats Nurix Therapeutics on 11 of the 16 factors compared between the two stocks.

How does Nurix Therapeutics compare to ImmunityBio?

ImmunityBio (NASDAQ:IBRX) and Nurix Therapeutics (NASDAQ:NRIX) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, profitability, media sentiment, valuation, risk and earnings.

ImmunityBio currently has a consensus target price of $14.20, suggesting a potential upside of 38.23%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 46.96%. Given Nurix Therapeutics' higher possible upside, analysts clearly believe Nurix Therapeutics is more favorable than ImmunityBio.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
ImmunityBio
1 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.86
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

ImmunityBio has a net margin of -598.55% compared to Nurix Therapeutics' net margin of -928.44%. ImmunityBio's return on equity of 0.00% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunityBio-598.55% N/A -51.65%
Nurix Therapeutics -928.44%-76.09%-57.31%

ImmunityBio has a beta of 0.02, meaning that its stock price is 98% less volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.82, meaning that its stock price is 82% more volatile than the broader market.

In the previous week, ImmunityBio had 1 more articles in the media than Nurix Therapeutics. MarketBeat recorded 9 mentions for ImmunityBio and 8 mentions for Nurix Therapeutics. ImmunityBio's average media sentiment score of 0.67 beat Nurix Therapeutics' score of 0.29 indicating that ImmunityBio is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
ImmunityBio
4 Very Positive mention(s)
1 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

8.6% of ImmunityBio shares are held by institutional investors. 66.1% of ImmunityBio shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Nurix Therapeutics has lower revenue, but higher earnings than ImmunityBio. ImmunityBio is trading at a lower price-to-earnings ratio than Nurix Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunityBio$113.29M96.11-$351.40M-$0.97N/A
Nurix Therapeutics$83.98M28.77-$264.46M-$3.45N/A

Summary

ImmunityBio beats Nurix Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Nurix Therapeutics compare to TG Therapeutics?

TG Therapeutics (NASDAQ:TGTX) and Nurix Therapeutics (NASDAQ:NRIX) are both mid-cap healthcare companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, earnings, institutional ownership, media sentiment, valuation, risk, analyst recommendations and dividends.

TG Therapeutics presently has a consensus target price of $63.00, suggesting a potential upside of 17.11%. Nurix Therapeutics has a consensus target price of $34.21, suggesting a potential upside of 46.96%. Given Nurix Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Nurix Therapeutics is more favorable than TG Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
TG Therapeutics
2 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.44
Nurix Therapeutics
1 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.80

In the previous week, Nurix Therapeutics had 4 more articles in the media than TG Therapeutics. MarketBeat recorded 8 mentions for Nurix Therapeutics and 4 mentions for TG Therapeutics. Nurix Therapeutics' average media sentiment score of 0.29 beat TG Therapeutics' score of 0.26 indicating that Nurix Therapeutics is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
TG Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Nurix Therapeutics
1 Very Positive mention(s)
0 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

TG Therapeutics has a net margin of 55.22% compared to Nurix Therapeutics' net margin of -928.44%. TG Therapeutics' return on equity of 73.49% beat Nurix Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
TG Therapeutics55.22% 73.49% 34.14%
Nurix Therapeutics -928.44%-76.09%-57.31%

TG Therapeutics has a beta of 1.8, indicating that its share price is 80% more volatile than the broader market. Comparatively, Nurix Therapeutics has a beta of 1.82, indicating that its share price is 82% more volatile than the broader market.

58.6% of TG Therapeutics shares are held by institutional investors. 8.9% of TG Therapeutics shares are held by company insiders. Comparatively, 6.7% of Nurix Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

TG Therapeutics has higher revenue and earnings than Nurix Therapeutics. Nurix Therapeutics is trading at a lower price-to-earnings ratio than TG Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
TG Therapeutics$616.29M13.36$447.18M$2.7419.63
Nurix Therapeutics$83.98M28.77-$264.46M-$3.45N/A

Summary

TG Therapeutics beats Nurix Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Nurix Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for NRIX and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NRIX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NRIX vs. The Competition

Export
MetricNurix TherapeuticsBiotechnology IndustryHealthcare SectorNASDAQ Exchange
Market Cap$2.39B$3.84B$7.10B$13.24B
Dividend YieldN/A3.64%2.53%15.88%
P/E Ratio-6.6612.99274.6126.05
Price / Sales28.411,288.54601.0289.39
Price / CashN/A121.7677.3851.25
Price / Book4.3516.6310.926.31
Net Income-$264.46M-$22.67M$3.50B$361.43M
7 Day Performance-0.09%-3.06%-2.11%-1.67%
1 Month Performance-10.96%-10.76%-6.34%-3.94%
1 Year Performance153.19%21.10%8.81%2.77%

Nurix Therapeutics Competitors List

Export
CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NRIX
Nurix Therapeutics
2.4089 of 5 stars		$22.99
-1.5%		$34.21
+48.8%		+148.3%$2.39B$83.98MN/A357
KYMR
Kymera Therapeutics
2.1363 of 5 stars		$112.00
+0.0%		$133.21
+18.9%		+101.5%$9.31B$39.21MN/A273
ARWR
Arrowhead Pharmaceuticals
2.9419 of 5 stars		$65.46
-0.7%		$98.31
+50.2%		+85.1%$9.29B$829.45MN/A711
PTGX
Protagonist Therapeutics
1.6418 of 5 stars		$142.44
+0.4%		$147.13
+3.3%		+117.5%$9.18B$46.02M138.29141
IBRX
ImmunityBio
2.8331 of 5 stars		$8.51
+0.8%		$14.20
+66.9%		+274.2%$8.95B$113.29MN/A691

Related Companies and Tools

Related Companies
Top 10 Stock Comparisons

This page (NASDAQ:NRIX) was last updated on 10/2/2026 by MarketBeat.com Staff.
From Our Partners
Elon Warns "America Will Go Bankrupt". Trump's Plan Inside.
National debt just crossed 40 trillion dollars, and Elon Musk says America is 1,000% going to go bankrupt with...
American Hartford Gold | Sponsoredtc pixel
MILLIONAIRE MASTERCLASS INVITE: Altucher
James Altucher says Elon Musk is preparing an unprecedented project set to surface on December 8th. Altuche...
Paradigm Press | Sponsoredtc pixel
The end of AI data centers coming?
Marc Chaikin's Power Gauge system flagged Micron before it soared 970 percent, Celestica before a 6,600 percen...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
The investigation Porter spent tens of thousands to document
Porter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...
Porter & Company | Sponsoredtc pixel
Major Buy Alert Issued for October 31st
Keith Kaplan has invested $17 million into his own AI research tools, building a platform now used by 180,000 ...
TradeSmith | Sponsoredtc pixel
They're not buying gold. They're buying this.
Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...
Behind the Markets | Sponsoredtc pixel
Bank of America: 'Digital Dollar Inevitable'
Bank of America just revealed your expiration date. In their Bloomberg interview, they didn't just predict the...
Decentralized Masters | Sponsoredtc pixel